A federal drug developer that DEA barred from testifying at its own rescheduling hearing says the agency's reasoning collapsed weeks later, when one of its scientific witnesses raised the exact issue the company had been blocked from addressing. MMJ International Holdings, which operates through subsidiaries MMJ BioPharma Cultivation and MMJ BioPharma Labs, is now pressing that contradiction before the U.S. Court of Appeals for the District of Columbia Circuit, where its challenge to the Attorney General's April 2026 Rescheduling Order remains pending.
The dispute matters well beyond one company's appeal. It touches the administrative machinery that determines how marijuana gets classified under federal law, and by extension, how state-licensed cannabis businesses, pharmaceutical developers, and compliance teams plan around a shifting regulatory floor. MMJ's position is unusual in this fight: rather than building a business on state commercial licensing, the way a dispensary might rely on a cannabis retail platform for Alaska to manage point-of-sale operations and inventory tracking, MMJ pursued FDA Investigational New Drug authorizations, orphan-drug designation, and a DEA-registered Schedule I laboratory. That distinction is central to its argument that DEA excluded the one participant positioned to speak to the federal drug-approval side of the record. cannabis retail platform for Alaska
What DEA Denied, and What Its Witness Later Said
DEA's June 17, 2026 denial letter, signed by Administrator Terrance C. Cole, concluded that MMJ's proposed testimony addressed legal questions rather than factual ones, and therefore fell outside what the hearing was meant to consider. Fair enough, on paper. But during the hearing itself, a DEA scientist from the agency's Scientific Review Division testified that state medical marijuana programs represent a significant source of diversion - and acknowledged that diversion was never analyzed in the 2023 Department of Health and Human Services scientific review underlying the rescheduling recommendation. That is not a minor gap. It means DEA's own hearing record surfaced an evidentiary hole that MMJ says it had specifically sought to address, only to be told its input wasn't factual enough to matter.
Why the Procedural Question Outlasts the Hearing Itself
MMJ's appeal rests on statutory grounds that predate this specific hearing dispute: whether the Controlled Substances Act required formal rulemaking before reclassification, and whether the government's reliance on treaty authority can substitute for the process Congress built into the statute. The company points to the D.C. Circuit's ruling in NORML v. DEA as limiting exactly that kind of shortcut. Excluding an affected party from the only administrative hearing held on the matter, MMJ argues, doesn't resolve those procedural questions - it adds another layer to them.
What Operators and Investors Should Take From This
For dispensary operators, multi-state operators, and compliance teams tracking the rescheduling process, the practical takeaway isn't about Schedule III timing predictions - nobody credibly has those yet. It's about record integrity. If the underlying administrative record is later found procedurally deficient, any Schedule III determination built on it becomes vulnerable to further litigation, which means banking access, 280E tax relief, and interstate research pathways that operators are counting on could remain unsettled longer than current optimism suggests. That uncertainty is worth building into business planning now, rather than assuming rescheduling is a settled outcome simply because an order was signed.
